FRM
AUPH icon

Fox Run Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Fox Run Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,121
Closed -$309K – 926
2026
Q1 		$309K Sell
22,121
-11,359
-34% -$166K 0.05% 614
2025
Q4 		$534K Buy
33,480
+6,778
+25% +$96.1K 0.08% 476
2025
Q3 		$295K Sell
26,702
-9,159
-26% -$100K 0.05% 688
2025
Q2 		$304K Sell
35,861
-9,101
-20% -$73K 0.05% 633
2025
Q1 		$361K Buy
44,962
+24,777
+123% +$201K 0.06% 616
2024
Q4 		$181K Buy
+20,185
New +$165K 0.03% 763
2024
Q3 		– Sell
-28,797
Closed -$164K – 795
2024
Q2 		$164K Buy
28,797
+1,545
+6% +$8.14K 0.03% 694
2024
Q1 		$137K Buy
+27,252
New +$185K 0.03% 685
2023
Q4 		– Sell
-15,391
Closed -$120K – 726
2023
Q3 		$120K Sell
15,391
-38,436
-71% -$376K 0.04% 610
2023
Q2 		$521K Buy
+53,827
New +$559K 0.15% 274
2023
Q1 		– Sell
-34,281
Closed -$148K – 650
2022
Q4 		$148K Buy
34,281
+6,788
+25% +$39.4K 0.06% 526
2022
Q3 		$207K Buy
+27,493
New +$238K 0.08% 470

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's AUPH Position: Q2 2026 in Review

Fox Run Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 22,121 shares — an estimated $309K sold.

Fox Run Management first reported a position in AUPH in Q3 2022 and held it in 12 quarters. The position peaked at $534K in Q4 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Fox Run Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 22,121 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $309K.
  • Fox Run Management first reported a position in Aurinia Pharmaceuticals in Q3 2022 and held it in 12 quarters.
  • Fox Run Management's Aurinia Pharmaceuticals position peaked at $534K in Q4 2025.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.